story of the week
Abemaciclib Plus Fulvestrant Improves Overall Survival in HR+, ERBB2− Breast Cancer That Progressed on Endocrine Therapy
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
JAMA Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor-Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy - MONARCH 2: A Randomized Clinical Trial
JAMA Oncol 2019 Sep 29;[EPub Ahead of Print], GW Sledge, M Toi, P Neven, J Sohn, K Inoue, X Pivot, O Burdaeva, M Okera, N Masuda, PA Kaufman, H Koh, EM Grischke, P Conte, Y Lu, S Barriga, K Hurt, M Frenzel, S Johnston, A Llombart-CussacFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.